Xbrane Biopharma (Sweden) Market Value
| XBRANE Stock | SEK 0.15 0.01 7.14% |
| Symbol | Xbrane |
Xbrane Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Xbrane Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Xbrane Biopharma.
| 12/17/2024 |
| 03/17/2025 |
If you would invest 0.00 in Xbrane Biopharma on December 17, 2024 and sell it all today you would earn a total of 0.00 from holding Xbrane Biopharma AB or generate 0.0% return on investment in Xbrane Biopharma over 90 days. Xbrane Biopharma is related to or competes with Hansa Biopharma, Vicore Pharma, XSpray Pharma, and Saniona AB. Xbrane Biopharma AB , a biopharmaceutical company, develops and manufactures biosimilars and generic long acting injecta... More
Xbrane Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Xbrane Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Xbrane Biopharma AB upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 19.17 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 6.67 |
Xbrane Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xbrane Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Xbrane Biopharma's standard deviation. In reality, there are many statistical measures that can use Xbrane Biopharma historical prices to predict the future Xbrane Biopharma's volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.28) | |||
| Total Risk Alpha | 0.2848 | |||
| Treynor Ratio | 0.3277 |
Xbrane Biopharma Backtested Returns
Xbrane Biopharma shows Sharpe Ratio of -0.0339, which attests that the company had a -0.0339 % return per unit of risk over the last 3 months. Xbrane Biopharma exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Xbrane Biopharma's Standard Deviation of 3.95, market risk adjusted performance of 0.3377, and Mean Deviation of 2.43 to validate the risk estimate we provide. The firm maintains a market beta of -0.64, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Xbrane Biopharma are expected to decrease at a much lower rate. During the bear market, Xbrane Biopharma is likely to outperform the market. At this point, Xbrane Biopharma has a negative expected return of -0.13%. Please make sure to check out Xbrane Biopharma's maximum drawdown, rate of daily change, as well as the relationship between the Rate Of Daily Change and relative strength index , to decide if Xbrane Biopharma performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.39 |
Poor reverse predictability
Xbrane Biopharma AB has poor reverse predictability. Overlapping area represents the amount of predictability between Xbrane Biopharma time series from 17th of December 2024 to 31st of January 2025 and 31st of January 2025 to 17th of March 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Xbrane Biopharma price movement. The serial correlation of -0.39 indicates that just about 39.0% of current Xbrane Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.39 | |
| Spearman Rank Test | -0.5 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Xbrane Biopharma lagged returns against current returns
Autocorrelation, which is Xbrane Biopharma stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Xbrane Biopharma's stock expected returns. We can calculate the autocorrelation of Xbrane Biopharma returns to help us make a trade decision. For example, suppose you find that Xbrane Biopharma has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Xbrane Biopharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Xbrane Biopharma stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Xbrane Biopharma stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Xbrane Biopharma stock over time.
Current vs Lagged Prices |
| Timeline |
Xbrane Biopharma Lagged Returns
When evaluating Xbrane Biopharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Xbrane Biopharma stock have on its future price. Xbrane Biopharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Xbrane Biopharma autocorrelation shows the relationship between Xbrane Biopharma stock current value and its past values and can show if there is a momentum factor associated with investing in Xbrane Biopharma AB.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Xbrane Stock
Xbrane Biopharma financial ratios help investors to determine whether Xbrane Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xbrane with respect to the benefits of owning Xbrane Biopharma security.